The "woo-woo" economy has crossed from crystals and cleanses into clinical trials and quarterly earnings. The Global Wellness Institute pegs the wellness economy at roughly $6.8 trillion, with mental wellness segments compounding at double digits: brain and sleep supplements above $93 billion growing about 13% annually, sensory mental health products near $107 billion, and meditation spending growing nearly 19% a year. The sharpest catalyst set sits in psychedelics, where an April 2026 executive order directed the FDA to fast-track psychedelic therapy reviews and AbbVie committed roughly $1 billion to the space. Compass Pathways reported positive Phase 3 psilocybin data in treatment-resistant depression and targets launch readiness by end of 2026, while Definium Therapeutics (formerly MindMed) has multiple pivotal readouts due this year. On the consumer side, functional nutrition names like BellRing Brands monetize the fibermaxxing and protein wave, while Lululemon shows the flip side: mindful-movement branding does not immunize a stock from competition and margin pressure. This briefing is risk-forward by design. Psychedelic names are pre-revenue, binary, and dilution-prone; consumer wellness names face fad decay and GLP-1 crosscurrents. Position sizes should reflect that most woo-woo catalysts are event-driven, not compounding. Nothing here is financial advice; it is a map of where real money and real trial data now intersect with a formerly fringe theme.
COMP360 posted positive Phase 3 results in treatment-resistant depression in June 2025, and the company targets launch readiness by end of 2026 with possible FDA approval in 2027. An April 2026 executive order instructing the FDA to prioritize psychedelic reviews is a rare regulatory tailwind for the whole category.
Shares trade near $13.64 with a market cap just above $1.2 billion. After a $150 million financing and roughly $200 million in warrant exercises, cash is guided to fund operations into 2028, reducing near-term dilution risk relative to peers.
The most de-risked pure play on medicalized psychedelics, but still a binary biotech.
The former MindMed rebranded to Definium in January 2026 with MM120 in Phase 3 for generalized anxiety disorder and major depressive disorder, plus topline data expected across its Emerge, Voyage, and Panorama studies this year. One Street target of $61 implies large upside, but sell-side euphoria after a quadruple is itself a warning.
Shares near $47.07 value the pre-revenue company around $4 billion after a fourfold run. Q3 losses widened to $0.78 per share as R&D surged to $31 million, and analysts model no revenue this fiscal year or next.
Highest torque to the psychedelic thesis, and the most punishing if 2026 data disappoints.
Brain, sleep, and gut supplements exceed $93 billion in annual spend growing about 13% a year, and 2026 trend reports put fiber and microbiome products at the center of mainstream wellness. BellRing's Premier Protein and Dymatize sit directly in that current, though the stock has been punished on growth deceleration fears.
Shares trade near $12.48, far below prior highs, implying the market is pricing shake category saturation rather than the 13% category CAGR. The gap between category growth and the stock's multiple is the trade.
A cash-generative way to own the supplement wave without biotech binary risk.
Mindful movement sits inside a $541 billion global physical activity spend pool, yet participation grows only about 1.2% annually versus much faster spending, and challenger brands like Alo and Vuori have broken Lululemon's pricing power. The stock's collapse from prior highs is the theme's cautionary tale.
Shares near $119.26 are down massively from peaks above $500, even as the wellness apparel category itself keeps growing. Cheap on trailing earnings, but Americas comp declines suggest the brand, not the category, is the problem.
Included as the honest counterweight: a wellness halo is not a moat.
This briefing is one run. Generate live macro intelligence across any sector, on demand, free.
🚀 Enter Just Signal